By Billy Candra 
Cambridge, UK – A groundbreaking study conducted by researchers at the University of Cambridge, in collaboration with the National Disease Registration Service (NDRS) in NHS England, has provided compelling evidence that bilateral salpingo-oophorectomy (BSO) – the surgical removal of the ovaries and fallopian tubes – significantly reduces the risk of early death and the development of second primary cancers in women diagnosed with breast cancer who carry pathogenic variants in the BRCA1 and BRCA2 genes. Published today in The Lancet Oncology, this large-scale investigation addresses long-standing uncertainties regarding the overall impact of BSO in this specific high-risk population, particularly concerning potential unintended consequences of early menopause.
For decades, women identified with BRCA1 and BRCA2 genetic mutations have been counselled on the elevated risks of developing ovarian and breast cancers. Prophylactic BSO has been a standard recommendation to mitigate the risk of ovarian cancer, a notoriously aggressive disease often diagnosed at an advanced stage. While previous research confirmed BSO’s efficacy in reducing ovarian cancer risk by as much as 80%, concerns persisted regarding the broader health implications of surgically induced menopause, especially for breast cancer survivors who may not be candidates for hormone replacement therapy (HRT). This new study, leveraging extensive NHS electronic health records, offers crucial reassurance by demonstrating a substantial reduction in all-cause and cancer-specific mortality, alongside a decreased incidence of second primary cancers, without an increased risk of adverse long-term outcomes like cardiovascular disease or depression.
The Prophylactic Imperative: Understanding BRCA and Cancer Risk
The BRCA1 and BRCA2 genes are critical tumor suppressor genes responsible for repairing damaged DNA and maintaining genomic stability. When these genes harbor pathogenic variants (mutations), their ability to function correctly is compromised, leading to a significantly increased lifetime risk of developing certain cancers, most notably breast and ovarian cancers. The prevalence of BRCA1 and BRCA2 pathogenic variants in the general population is estimated to be approximately 1 in 400 to 1 in 800 individuals, though this varies across different ethnic groups.
For women carrying a BRCA1 pathogenic variant, the lifetime risk of developing breast cancer can range from 40% to 85%, and the lifetime risk of ovarian cancer can be as high as 20% to 60%. For BRCA2 carriers, the lifetime breast cancer risk is similarly elevated, between 40% and 85%, while the ovarian cancer risk typically ranges from 10% to 30%. These figures represent a stark contrast to the general population’s lifetime risks, which are approximately 13% for breast cancer and less than 2% for ovarian cancer. Given these elevated risks, clinical guidelines globally recommend proactive management strategies, including intensified surveillance and risk-reducing surgeries.
Prophylactic BSO has been a cornerstone of ovarian cancer prevention for BRCA carriers. Current recommendations suggest the procedure for BRCA1 carriers between the ages of 35 and 40, or upon completion of childbearing, and for BRCA2 carriers between the ages of 40 and 45. These age ranges are strategically chosen to precede the typical onset of ovarian cancer in these high-risk populations, while balancing quality of life considerations. However, the decision to undergo BSO is complex, particularly for women who have already faced a breast cancer diagnosis.
Addressing the Unanswered Questions: Early Menopause and Systemic Impact
The primary hesitation surrounding BSO, particularly in breast cancer survivors, has stemmed from the inevitable onset of early menopause. The ovaries are the body’s main source of estrogen, and their removal triggers an abrupt and often more severe menopausal transition than natural menopause. Symptoms can include hot flashes, night sweats, vaginal dryness, mood swings, and cognitive changes. More significantly, the long-term absence of estrogen has been historically linked to an increased risk of cardiovascular disease, osteoporosis, and potentially cognitive decline in the general population. For breast cancer patients, the situation is further complicated by the fact that HRT, often used to manage menopausal symptoms, is typically contraindicated due to concerns about stimulating breast cancer recurrence or growth.
This creates a challenging dilemma: while BSO offers profound protection against ovarian cancer, the overarching impact on the health and longevity of breast cancer patients with BRCA variants remained an area of significant uncertainty. Conventional research methodology, such as randomized controlled trials (RCTs) – considered the ‘gold standard’ for evaluating treatment efficacy and safety – would be ethically unfeasible in this context. Randomizing BRCA carriers to either receive BSO or not would expose the control group to an unacceptably high and preventable risk of developing ovarian cancer, rendering such a trial morally indefensible.
A Novel Approach: Harnessing the Power of NHS Data
To circumvent these ethical barriers, the Cambridge research team ingeniously utilized a wealth of real-world data. They collaborated with the National Disease Registration Service (NDRS) in NHS England, accessing electronic health records and data from NHS genetic testing laboratories. This allowed them to analyze long-term outcomes for a large cohort of BRCA1 and BRCA2 pathogenic variant (PV) carriers who had been diagnosed with breast cancer.
The study identified a total of 3,400 women carrying one of these cancer-causing variants, split almost equally between BRCA1 and BRCA2 carriers (approximately 1,700 for each). Within this cohort, around 850 BRCA1 carriers and 1,000 BRCA2 carriers had undergone BSO surgery. By comparing the health trajectories of women who had undergone BSO with those who had not, the researchers could meticulously assess the procedure’s impact.
Key Findings: A Clear Survival Advantage and Reduced Secondary Cancers
The results, published in The Lancet Oncology, represent a significant milestone in informing clinical practice. The study found that women who underwent BSO were approximately half as likely to die from cancer or any other cause during the median follow-up period of 5.5 years. This substantial reduction in early mortality underscores a clear survival benefit associated with the procedure.
Breaking down the findings by gene, the reduction in early death was even more pronounced in BRCA2 carriers, who experienced a 56% lower risk, compared to a 38% reduction in BRCA1 carriers. This differential effect warrants further investigation but suggests potentially distinct biological mechanisms or cancer profiles associated with each gene mutation.
Beyond the remarkable survival benefit, the study also revealed another crucial advantage: women who underwent BSO were at around a 40% lower risk of developing a second primary cancer. This finding is particularly important for BRCA carriers, who inherently face elevated risks of multiple primary cancers throughout their lives. While the precise mechanism for this reduction in second cancers requires further exploration, it suggests a systemic protective effect potentially related to the removal of ovarian hormones.
Importantly, the researchers meticulously searched for any evidence of adverse long-term outcomes previously hypothesized to be linked with early menopause. Reassuringly, the study found no increased risk of heart disease, stroke, or depression among women who had undergone BSO. This directly contradicts some earlier studies conducted in the general population, which had suggested a link between BSO and an elevated risk of these conditions. The difference in findings may be attributed to the specific genetic context of the BRCA carriers, their existing cancer diagnosis, or other confounding factors present in general population studies. While the team acknowledged that proving 100% causality is challenging in observational studies, the strength and consistency of the evidence strongly point towards BSO being the cause of these beneficial outcomes.
Expert Perspectives and Clinical Implications
Hend Hassan, a PhD student at the Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, and Wolfson College, Cambridge, and the study’s first author, emphasized the significance of these findings. "We’ve known for a long time that removing the ovaries and fallopian tubes dramatically reduces the risk of ovarian cancer. However, there has always been a significant question mark over the potential unintended consequences of the sudden onset of menopause this procedure causes," Hassan stated. "Our research now provides much-needed clarity, demonstrating that for women with a personal history of breast cancer, BSO offers clear benefits in terms of overall survival and a lower risk of developing other cancers, crucially without the adverse side effects such as heart conditions or depression that were previously a concern."
Professor Antonis Antoniou, from the Department of Public Health and Primary Care and the study’s senior author, highlighted the immediate clinical relevance. "Our findings will be absolutely crucial for counselling women with cancer linked to one of the BRCA1 and BRCA2 variants," Professor Antoniou affirmed. "This evidence empowers them to make truly informed decisions about whether or not to opt for this life-altering operation, providing a more complete picture of its benefits and the absence of certain previously feared risks." Professor Antoniou, who also directs the Cancer Data-Driven Detection programme, further noted the profound impact of robust national health datasets: "This study also powerfully illustrates the exceptional potential of NHS datasets in driving impactful, clinically relevant research that directly translates into improved patient care."
Addressing Health Equity and Disparities in Care
Despite the clear benefits identified, the study uncovered concerning disparities in BSO uptake. The research revealed that most women undergoing BSO were white. Black and Asian women were found to be approximately half as likely to have BSO compared to white women. Furthermore, women residing in less deprived areas were more likely to undergo the procedure compared to those in the most-deprived categories.
These findings highlight a critical challenge in health equity. Hend Hassan expressed concern: "Given the clear benefits that this procedure provides for at-risk women, it’s deeply concerning that some groups of women are less likely to undergo it. We urgently need to understand the underlying reasons for these disparities – whether they relate to access to genetic testing, cultural factors, communication barriers, or socio-economic determinants – and actively work to encourage uptake among these underserved populations to ensure equitable access to life-saving interventions." This calls for targeted public health campaigns, improved genetic counseling accessibility, and culturally sensitive outreach programs to bridge these gaps.
Broader Implications and Future Directions
This study marks a pivotal moment in the management of BRCA-associated cancers. It provides robust, real-world evidence that will undoubtedly influence clinical guidelines globally, strengthening the recommendation for prophylactic BSO in BRCA1 and BRCA2 carriers with a prior breast cancer diagnosis. For oncologists, genetic counselors, and primary care physicians, these findings offer a clearer, more reassuring narrative to share with patients navigating complex risk-reduction decisions.
The success of this study also underscores the immense value of large-scale, population-based electronic health record data. In situations where traditional RCTs are unethical or impractical, leveraging meticulously collected and curated national health datasets offers a powerful alternative for generating high-quality evidence that can directly inform clinical practice and public health policy. This methodology sets a precedent for future research into rare conditions or ethically sensitive interventions.
Future research will likely focus on several areas. Delving deeper into the differential effects observed between BRCA1 and BRCA2 carriers could provide insights into distinct biological pathways and potentially lead to more personalized risk-reduction strategies. Investigating the precise mechanisms by which BSO reduces the risk of second primary cancers, beyond simply removing the ovaries, could also uncover novel therapeutic targets. Furthermore, detailed qualitative and quantitative studies are needed to understand the barriers to BSO uptake in diverse demographic groups and to develop effective interventions to address health inequities.
The research was generously funded by Cancer Research UK, with additional support from the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre. The University of Cambridge and Addenbrooke’s Charitable Trust (ACT) are actively fundraising for a new hospital, the Cambridge Cancer Research Hospital. This partnership with Cambridge University Hospitals NHS Foundation Trust aims to transform cancer diagnosis and treatment across the East of England, with the research conducted within its walls promising to profoundly impact the lives of cancer patients throughout the UK and internationally. This latest study is a testament to the type of impactful, life-changing research such institutions are poised to deliver.